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Mice modela b s t r a c t
The efforts for the development and testing of vaccines against Trypanosoma cruzi infection have
increased during the past years. We have designed a TcVac series of vaccines composed of T. cruzi derived,
GPI-anchored membrane antigens. The TcVac vaccines have been shown to elicit humoral and cellular
mediated immune responses and provide significant (but not complete) control of experimental infection
in mice and dogs. Herein, we aimed to test two immunization protocols for the delivery of DNA-prime/
DNA-boost vaccine (TcVac1) composed of TcG2 and TcG4 antigens in a BALB/c mouse model. Mice were
immunized with TcVac1 through intradermal/electroporation (IDE) or intramuscular (IM) routes, chal-
lenged with T. cruzi, and evaluated during acute phase of infection. The humoral immune response
was evaluated through the assessment of anti-TcG2 and anti-TcG4 IgG subtypes by using an ELISA.
Cellular immune response was assessed through a lymphocyte proliferation assay. Finally, clinical and
morphopathological aspects were evaluated for all experimental animals. Our results demonstrated that
when comparing TcVac1 IDE delivery vs IM delivery, the former induced significantly higher level of
antigen-specific antibody response (IgG2a + IgG2b > IgG1) and lymphocyte proliferation, which
expanded in response to challenge infection. Histological evaluation after challenge infection showed
infiltration of inflammatory cells (macrophages and lymphocytes) in the heart and skeletal tissue of all
infected mice. However, the largest increase in inflammatory infiltrate was observed in TcVac1_IDE/Tc
mice when compared with TcVac1_IM/Tc or non-vaccinated/infected mice. The extent of tissue inflam-
matory infiltrate was directly associated with the control of tissue amastigote nests in vaccinated/
infected (vs. non-vaccinated/infected) mice. Our results suggest that IDE delivery improves the protective
efficacy of TcVac1 vaccine against T. cruzi infection in mice when compared with IM delivery of the
vaccine.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).hances
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Trypanosoma cruzi is the causative agent of devastating Chagas
disease in Latin America. Most common route of parasite transmis-
sion to humans is through blood-sucking triatomines. Chagas dis-
ease is characterized by an acute and a chronic phase. Once the
acute parasitemia abates, most of the infected individuals attain
a less fulminant chronic infection. Several years after the infection,
20–35% of the infected individuals develop irreversible lesions of
the autonomous nervous system of the heart, and/or esophagus,
colon, and peripheral nervous system. Chagas disease represents
the major cause of cardiac lesions in young, economically produc-
tive adults in the endemic countries [1,2]. Vector control programs
have not been able to completely prevent parasite transmission
[3], the available anti-parasitic drugs are not sufficiently safe or
effective, and no vaccines are currently available [4].
The studies of immune responses in resistant and susceptible
models of Chagas disease have been valuable in enhancing our
knowledge of the protective immunity and designing of the vacci-
nation approaches against T. cruzi infection. The sequencing of T.
cruzi genome and the development of approaches to produce
recombinant proteins have made it feasible to produce, deliver,
and test the efficacy of a variety of recombinant T. cruzi antigens
as potential vaccine candidates in experimental models of infection
and disease [5–7]. Indeed, many of the recombinant antigens have
been tested as prophylactic vaccines. However, recombinant pro-
tein based vaccines failed to provide high efficacy in controlling
T. cruzi infection [8,9]. This is, at least, partially due to the fact that
recombinant proteins elicited potent anti-T. cruzi antibody
response, but failed to stimulate cellular immunity that is required
to control the intracellular replicative form of the parasite. Thus,
new candidate antigens as well as new delivery approaches are
required to design an efficacious vaccine against T. cruzi infection.
Our group has performed computational screening of T. cruzi
sequence databases reported in GenBank and identified genes
encoding glycosylphosphatidylinositol (GPI)-anchored proteins as
potential vaccine candidates [5]. Through rigorous analysis over a
period of several years, we determined that two of the selected
candidate antigens, named TcG2 and TcG4, were maximally rele-
vant for the vaccine development. These two antigens are phyloge-
netically conserved in a variety of T. cruzi lineages, expressed in
infective and intracellular stages of the parasite’s life cycle, and
are recognized by immunoglobulins (IgGs) and CD8+ T cells in mul-
tiple T. cruzi-infected hosts [10]. Intramuscular co-delivery of these
antigens as DNA vaccine (TcVac1) induced higher degree of protec-
tion from T. cruzi infection than was observed by delivery of single
antigens in mice [7]. In dogs, TcVac1 candidate vaccine elicited a
significant trypanolytic antibody and Th1 cytokine (IFN-c)
response, a property that has been associated with immune control
of T. cruzi [11].
Antigen delivery methods can result in varying quality and
quantity of immune responses. Physical delivery systems, such as
electroporation, micro-injection, gene gun, tattooing, laser and
ultrasound have been tested for the delivery of DNA-based vacci-
nes against infectious agents [12]. Electroporation (EP) induces
the formation of aqueous pores in lipid bilayers by the application
of a brief (microseconds to milliseconds), high-voltage pulse to
overcome the barrier of the cell membrane. This transient perme-
abilized state is used to load cells with a variety of different mole-
cules including ions, drugs, dyes, tracers, antibodies, RNA and DNA
[13]. Electroporation of DNA in vivo has proved to be an effective
method, yielding higher level of the cellular uptake of DNA,
increase in the number of DNA-transfected cells, and reduced
inter-subject variability. Electroporation of DNA vaccine also pro-Please cite this article as: W. Hegazy-Hassan, J. A. Zepeda-Escobar, L. Ochoa-Gar
vaccine induced immune protection against Trypanosoma cruzi infection in mivided increased magnitude of gene expression while requiring less
time to reach a maximal immune response when compared to the
conventional intramuscular approach of DNA vaccine delivery [14].
Increased efficacy of DNA vaccines delivered by electroporation
method vs. other methods, has been shown against a wide range
of infectious diseases, such as influenza, HIV, hepatitis C, malaria,
and anthrax [15]. Electroporation has also been tested for the
delivery of drugs and vaccines against a variety of cancers [16,17].
Herein, we describe the protective efficacy of TcVac1 vaccine
applied through an intradermal electroporation (IDE) approach.
The TcVac1 vaccine was injected in mice via IDE or intramuscular
(IM) approach, and mice were then challenged with T. cruzi. We
have analyzed the function of vaccine-induced antibody and lym-
phocyte responses in providing protection from acute parasitemia
in mice. We also performed histopathological examination of the
heart and skeletal muscle, focusing on the efficacy of vaccination
protocol in reducing the tissue injury during the acute T. cruzi
infection.2. Materials and methods
2.1. Ethics statement
All experimental protocols were conducted under the technical
specifications for the production, care and use of laboratory ani-
mals of the official Mexican standards (NOM-62-ZOO-1999) [18].
The Laboratory Animal Care Committee at the School of Veterinary
Medicine and Zootechnics of the Autonomous Mexico State
University (UAEM, Toluca, Mexico) approved all protocols.
2.2. Mice and parasites
BALB/c female mice (6–8 weeks old, n = 48) were purchased
from CINVESTAV, IPN, Mexico. T. cruzi trypomastigotes (Sylvio
10X/4 strain) were cultivated in continuous monolayer of Vero cell
line. Vero cells were propagated in Dulbecco’s minimal essential
medium (DMEM) supplemented with 2% fetal bovine serum
(FBS) and 1% penicillin-streptomycin, and cultured under con-
trolled conditions (37 C, 5% CO2, and saturated humidity) [19].
All media components were purchased from Gibco Laboratories,
USA.
2.3. TcVac1 vaccine
The cDNAs encoding for TcG2 and TcG4 (Sylvio X10/4 isolate,
GenBank: AY727915 and AY727917, respectively) cloned in
eukaryotic expression plasmids (pcDNA3.1.TcG2 and pCDNA3.1.
TcG4,), plasmids encoding IL-12 (pcDNA3.1-msp35 and
pcDNA3.1-msp40), and GM-CSF (pcMVI.GM-CSF) have been previ-
ously described [5,7]. All plasmids were transformed into E. coli
DH5-a competent cells, grown in LB-broth containing 100-mg/ml
ampicillin, and purified using the GeneJET Plasmid Maxiprep Kit
(Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA)
according to manufacturer’s specifications. The vaccine was consti-
tuted of 25-mg of each plasmid and delivered in 50 ml final volume
per mouse.
2.4. Immunization and challenge infection
Mice were randomly distributed to treatment groups (n = 12
per group) as follows: group I, Only empty pcDNA3.1 plasmid
(25 mg/mouse) via intradermal electroporation (IDE) ± challenge
infection; group II, TcVac1 DNA vaccine (25 mg each from the 5cía et al., TcVac1 vaccine delivery by intradermal electroporation enhances
ce, Vaccine, https://doi.org/10.1016/j.vaccine.2018.11.041
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tion; group III, Only empty pcDNA3.1 plasmid (25 mg/mouse)
via intramuscular (IM) ± challenge infection; and group IV,
TcVac1 DNA vaccine (25 mg each from the 4 DNA plasmids com-
posing the vaccine/mouse) via IM ± challenge infection. Six ani-
mals from each group were sacrificed to evaluate the vaccine
previous to the infection and the remaining six animals from
each group were infected and then evaluated during the acute
phase of the disease.
Animals were given DNA vaccine (TcVac1) or placebo (pcDNA3)
by intramuscular (IM) injection in the quadriceps muscle or by
intradermal electroporation (IDE). The vaccine, or placebo, was
delivered four times, at 3 weeks intervals. For IDE, mice were
sedated (ketamine/xylazine mix, contains: 87.5 mg/kg Ketamine
and 12.5 mg/kg Xylazine, 0.1 ml/20 g mouse wt. IP injected) and
shaved at the lower dorsal area, just above the tail base, and
TcVac1 DNA vaccine was delivered by intradermal injection.
Immediately afterwards, electroporation was performed at the site
of injection with 5 pulses at 450 V/cm2, 0.050-msec pulse interval
and 0.125-msec band width by using a Cyto Pulse SciencesTM PA-
4000 PulseAgile electroporation system. This device consists of
4  4 electrode array with 1.5-mm spacing to provide optimal cov-
erage on the DNA injection site [20].
Two weeks after the last immunization, mice were either
utilized for assessing the vaccine induced immune responses or
challenged with Sylvio 10X/4 strain of T. cruzi (10,000
trypomastigotes/mouse, intraperitoneally). Sixty days’ later, by
the end of the acute phase of infection, mice were sacrificed, and
blood was collected for serological evaluation, spleen was collected
for lymphocyte activation assays, and heart and skeletal muscle
were dissected and prepared for histological analyses.
2.5. Blood sample collection
Mice blood was obtained directly from heart at the time of sac-
rifice [21]. Blood samples were allowed to clot at 4 C and serum
was collected and stored at 20 C.
2.6. Lymphocyte proliferation
Spleens were dissected out in sterile conditions, washed in ice-
cold 1X PBS, and meshed using a 40 mm Nylon Cell Strainer (Corn-
ing, USA). The cells were washed and suspended in 1.5 ml of PBS,
gently laid over sterile-filtered Histopaque-1077 (1.5 ml, density:
1.077 g/mL, Sigma-Aldrich, USA), and centrifuged at 2300 rpm for
30 min at room temperature. Splenocytes were carefully collected,
washed twice with PBS, and resuspended in RPMI-1640 medium
(Sigma-Aldrich) supplemented with 10% FBS (Sigma-Aldrich).
Splenocytes (2  105 cells per well) were added to Nunc Maxisorp
96 well tissue culture plates (#M9410) and incubated for 48 h in
presence or absence of T. cruzi trypomastigotes lysate (TcTL) [22]
or recombinant TcG2 or TcG4 antigens (10 lg/ml). Splenocytes
incubated with phytohemagglutinin (PHA, Thermo Scientific) were
used as positive control. The CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega) was used to measure the number of
viable cells. Briefly, cells were incubated with MTS tetrazolium salt
(10 ml MTS/100 ml), and its reduction to colored formazan product
was recorded at 490 nm by using an EPOCH microplate spec-
trophotometer (BioTek Instruments, Winooski, VT, USA). Stimula-
tion index (StI) was defined as the ratio of the absorbance signal
observed in the negative control (C) and in the stimulated cells
(S) and calculated as follows:
StI ¼ S Cð Þ=CPlease cite this article as: W. Hegazy-Hassan, J. A. Zepeda-Escobar, L. Ochoa-Gar
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(TcG2, TcG4, TcTL and PHA) and negative control cells (wells con-
taining only splenocytes and RPMI-1640 medium), respectively.
A mice group (n = 6), treated with saline solution, was used to
calculate the cutoff value and was represented as follow: mean
StI of all negative control groups (saline, pcDNA3.1-IDE and
pcDNA3.1-IM) ± SD before and after challenge infection.
2.7. Serology
Sera samples were obtained two-weeks after the last immu-
nization and 60 days post challenge infection, according to previ-
ous reports [10] Briefly: Flat bottom, 96 well, Nunc Maxisorp
plates were coated with either T. cruzi lysate or recombinant
TcG2 or TcG4 proteins (500 ng/well/100 ml) diluted in 0.05 M
NaCO3/NaHCO3, pH 9.6 buffer. Protein concentration was standard-
ized in an independent assay to choose the optimal concentration
for the assay from 1, 2.5 and 5 ng/well/100 ml. Plates were washed
twice with PBS-0.05% Tween 20 (PBST), and blocked with (5% non-
fat dry milk -PBST). Plates were washed again, and incubated at
37 C for 2 h each with sera samples (1:50 dilution, 200 ml/well)
and horseradish peroxidase-conjugated goat anti-mouse IgG,
IgG1, IgG2a, or IgG2b antibodies (1:5000 dilution in PBST-3%
non-fat dry milk (NFDM)). All washing steps were carried out by
using an ELx50TM strip washer (BioTech), and all antibodies were
purchased from Bethyl Laboratories, Inc. Color was developed by
incubation with 100-ml/well Sure Blue TMB substrate (Kirkegaard
& Perry Labs) at room temperature for 15 min, reaction was
stopped with 2 N sulfuric acid, and change in color was monitored
at 450 nm using an Epoch microplate reader. Serum from known
positive (n = 6) and known negative (n = 6) mice, were used in
the ELISA assay for positive and negative controls, respectively.
The cut off value was established at the mean value + 2 SD of the
negative controls. Positive controls were always above that value.
2.8. Parasitemia and mortality
Blood samples were collected beginning 7 days post-infection
(pi), on alternated days, up to 50 days pi. Fresh blood smears were
analyzed by light microscopy at 400 final magnification, and par-
asites were counted in all microscopic fields per slide [23]. Mortal-
ity was recorded daily and a survival rate analysis was conducted,
results were analyzed statistically by Mantel-Cox test.
2.9. Histology
Six mice per group were sacrificed humanly under anesthesia
on day 15 after last immunization and the remaining six mice were
sacrificed at 60 days post challenge infection. Samples from skele-
tal muscle and heart were fixed in 10% formaldehyde and embed-
ded in paraffin [24]. Serial sections of five mm thicknesses were
prepared from non-consecutive areas, stained with hematoxylin
and eosin (H&E), and at least five sections per tissue for each
mouse were examined for the presence of acute inflammation
and parasite nests (magnification: 400 and 100).
2.10. Tissue parasitism and inflammation score
Tissue parasitism was evaluated by counting the amastigotes
nests present in 100 microscopic fields in each of the analyzed
organs. Likewise, inflammatory infiltrate was visualized in >200
microscopic fields of the tissue sections from heart and skeletal
muscle, and scored using the following score system (ordinal
method):cía et al., TcVac1 vaccine delivery by intradermal electroporation enhances
ce, Vaccine, https://doi.org/10.1016/j.vaccine.2018.11.041
Histopathological scoring system key
Parameters/Score 0 1 2 3 4
Focal lympho-plasmocytes None (0%) Rare (1–10%) Slight (11–25%) Moderate (26–50%) Severe (  51%)
Diffused lymphoplasmocytes None (0%) Slight (1–10%) Moderate (11–40%) Coalescing (41–80%) Diffuse (  80%)
Polymorphnuclear
Leukocyte/lymphocyte
None (0%) Rare (1–10%) Slight (11–20%) Moderate (21–30%) Severe (  31%)
Necrosis None (0%) Rare (1–5%) Slight (6–10%) Moderate (11–30%) Severe (  31–70%)
Amastigotes nests None (0%) Few (1–2) Slight (3–5) Moderate (6–10) Severe (  11)
4 W. Hegazy-Hassan et al. / Vaccine xxx (xxxx) xxxScore criteria was based on previous studies [24,25]. Three pathol-
ogists blindly analyzed the samples, and final consensus results
were recorded.
2.11. Statistical analysis
Female BALB/c mice of 6–8 weeks age were randomly dis-
tributed and divided into six groups (n = 12) for homogeneity of
variances among each other [26]. Treatments were randomly
assigned to the experimental units with six animals per treatment
before challenge and six after challenge infection.
One-way analysis of variance (ANOVA) followed by Tukey mul-
tiple comparison test were used to assess differences between ani-
mal groups in quantitative data; meanwhile, Fisher’s Exact test was
used for qualitative and semi-quantitative data. All statistical anal-
ysis was processed using (SAS University Edition Software) and
GraphPad Prism 6 software.3. Results
3.1. Effect of route of vaccine delivery on antigen-specific lymphocyte
proliferation before and after challenge infection
We monitored the splenic cell response to TcG2, TcG4 and TcTL
at two weeks after vaccination and 60 days after challenge infec-
tion. The TcVac1_IDE mice exhibited a significant increase in
TcG2- and TcG4- specific splenic lymphocytes’ proliferation that
was not noted in mice given TcVac1 via IM route. This wasTable 1
Lymphocyte proliferation stimulation index assay for TcVac1 IDE- and IM-vaccinated mic
A













Mice were given empty pCDNA3.1 plasmid, or TcVac1 vaccine by intradermal electropor
half number of mice in each group was challenged with T. cruzi (1-B). Splenocytes were i
(TcTL), or phytohemagglutinin (PHA, T cell mitogen, assay positive control) for 72 h. The l
index value and derived from at least triplicate observations per sample (n = 6 mice per gr
differences by using one-way analysis of variance ANOVA and Tukey’s multiple compar
normal distribution using Normality Test (Kolmogorov-Smirnov) and indicated that da
statistical differences between TcVac1-IDE or -IM vs pcDNA3.1-IDE or IM, respectively,
considered positive for values  1.14 ± 0.10, SE: Mean standard error.
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in TcVac1_IDE vs. TcVac1_IM mice (1.32, 1.63, and 1.80 vs. 1.04,
1.13, and 1.47, respectively; p < 0.0001) (Table 1-A). All spleno-
cytes, irrespective of the vaccination status, responded to PHA
stimulation with a potent increase in T cell proliferation. Splenic
cells harvested from control mice (n = 6) injected with empty vec-
tor exhibited no stimulation in response to T. cruzi antigens; thus,
confirming the observed splenic response in vaccinated mice was
antigen-specific.
After challenge infection, mice in all groups exhibited a
significant level of T. cruzi-specific lymphocytes proliferation.
Non-Statistically significant effects of TcVac1 (IDE vs. IM) on
TcTL-specific lymphocytes’ proliferation were observed in
challenged mice (Table 1-B). The vaccine-induced TcG2- and
TcG4-specific T cell proliferation increased by 3-fold post challenge
infection, and was strongest in TcVac1_IDE mice (p < 0.0001). In
comparison, TcVac1_IM mice exhibited similar level of antigen-
specific lymphocyte response as was noted in challenged mice
injected with pcDNA3 only. Together, these results suggest that
IDE (vs. IM) delivery of TcVac1 elicits a stronger, antigen-specific
lymphocytes’ response in vaccinated and vaccinated/challenged
mice.3.2. Effect of route of vaccine delivery on antigen-specific antibody
response (± T. cruzi)
Immunoglobulin G (IgG) and IgG subtypes (IgG1, IgG2a, IgG2b)
titers were evaluated two-weeks after the last vaccine dose ande before and after challenge infection.
SE P-value
pcDNA3.1_IM TcVac1_IM
1.05 1.04 0.027 < 0.0001
1.06 1.13 0.031 < 0.0001
1.12 1.47* 0.038 < 0.0001
3.48 3.54 0.162 < 0.0001
SE P-value
pcDNA3.1_IM TcVac1_IM
1.85 2.09 0.139 < 0.0001
1.97 2.39 0.199 < 0.0001
1.84 1.85 0.175 < 0.0001
3.80 3.33 0.178 < 0.0001
ation (IDE) or intramuscular (IM) injection (1-A). Two weeks after last vaccine dose,
ncubated with recombinant TcG2 and TcG4 proteins, T. cruzi trypomastigotes lysate
ymphocytes’ proliferation was recorded and data are presented as mean stimulation
oup), fully described in Materials and Methods. Results were analyzed for significant
ison test, and statistical differences are shown at a p < 0.0001. Data was tested for
ta was drawn from a population with a normal distribution (P > 0.200). *: Shows
**: Shows statistical differences between TcVac1-IDE vs TcVac1-IM. Samples were
cía et al., TcVac1 vaccine delivery by intradermal electroporation enhances
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Fig. 1. Antigen-specific antibody response in mice vaccinated with TcVac1 via IDE
or IM route. Mice were immunized as detailed in Material and Methods, T. cruzi
specific IgG and subtypes (IgG1, IgG2a, IgG2b) were assessed by ELISA assay by
using sera samples at 1:50 dilution. Data are presented as mean value ± SD, and
derived from triplicate observations by sample per mouse (n = 6 mice per group).
Vector was expressed as mean value of pcDNA3.1-IDE and -IM data. Results were
analyzed for significant differences by using one-way analysis of variance ANOVA
and Tukey’s multiple comparison test. *: show statistical differences between
TcVac1-IDE or -IM vs Vector for each IgG or IgG subtype at a p < 0.05. **: show
statistical differences between TcVac1-IDE vs TcVac1-IM for each IgG or IgG
subtype at a p < 0.05.
Fig. 2. Antigen-specific antibody response to challenge infection in mice vaccinated
with TcVac1 via IDE or IM route. Mice were immunized and infected as detailed in
Material and Methods. T. cruzi specific IgG and subtypes (IgG1, IgG2a, IgG2b) were
assessed by an ELISA assay, using the sera samples at 1:50 dilution. Data were
expressed as mean value ± SD, and derived from triplicate observations by sample
per mouse (n = 6 mice per group). Vector was expressed as mean value of
pcDNA3.1-IDE and -IM data. Results were analyzed for significant differences by
using one-way analysis of variance ANOVA and Tukey’s multiple comparison test. *:
show statistical differences between TcVac1-IDE or -IM vs Vector for each IgG or IgG
subtype at a p < 0.05. **: show statistical differences between TcVac1-IDE vs TcVac1-
IM for each IgG or IgG subtype at a p < 0.05.
W. Hegazy-Hassan et al. / Vaccine xxx (xxxx) xxx 560 days post-challenge with T. cruzi. Vaccination with TcVac1, irre-
spective of delivery route, elicited an antigen-specific antibody
response in mice (Fig. 1). A higher level of IgG as well as IgG sub-
type response to TcG2 (Fig. 1A) and TcG4 (Fig. 1B) antigens was
observed in TcVac1_IDE (vs. TcVac1_IM) group (p < 0.0001). Mice
vaccinated with TcVac1 by IDE route exhibited 35.3%, 45.8%,
45.6% and 29.7% increase in TcG2-specific and 42.9%, 71.0%,
53.0% and 43.9% increase in TcG4-specific IgG, IgG1, IgG2a and
IgG2b response, respectively, when compared to that noted in mice
vaccinated through IM route (Fig. 1A&B, all, p < 0.05). The TcG2-
specific IgG2a/b response was dominant in TcVac1_IDE group. In
comparison, IM delivery of TcVac1 elicited low levels of TcG2-
and TcG4-specific IgG and IgG2a, and non-significant changes in
the IgG2b and IgG1 levels when compared with vector controls
(Fig. 1A&B). These results suggest that IDE delivery of TcVac1 elic-
its stronger, antigen-specific antibody response than was observed
with IM delivery of the vaccine.
The antibody response monitored at 60 days post-challenge
infection in vaccinated and control mice is presented in Fig. 2. All
mice responded to challenge infection with a significant increment
in anti-parasite antibody response. The levels of TcG2- and TcG4-
specific total IgG and IgG subtypes (IgG1, IgG2a, IgG2b) were sig-
nificantly higher in vaccinated/infected, vs. non-vaccinated/
infected, mice (Fig. 2A&B; p < 0.05). The TcVac1_IDE/Tcmice exhib-
ited 28.5%, 19.3%, 25.7% and 42.9% increase in TcG2-specific and
28.4%, 18.3%, 24.8% and 37.0% increase in TcG4-specific IgG, IgG1,
IgG2a and IgG2b responses, respectively, when compared to that
observed in TcVac1_IM/Tc mice (Fig. 2A&B). Likewise, T. cruzi-
specific antibody response was detected in all mice post-Please cite this article as: W. Hegazy-Hassan, J. A. Zepeda-Escobar, L. Ochoa-Gar
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and IgG subtypes were noted in TcVac1_IDE/Tc group, while mice
in TcVac1_IM/Tc and pcDNA3/Tc groups exhibited significantly
higher levels of IgG1 than was noted in TcVac1_IDE/Tc mice
(Fig. 2C). Together, the results presented in Fig. 2, along with those
presented in Fig. 1 suggest that TcVac1 delivery by IDE (vs. IM)
route elicits a strong, antigen-specific and parasite-specific anti-
body response that significantly expanded upon challenge infec-
tion. In comparison, non-vaccinated mice responded to challenge
infection with low antigen-specific antibody levels.
3.3. Parasitemia and mortality in vaccinated/infected mice
Challenge infection with SylvioX10 isolate of T. cruzi did not
produce detectable blood parasitemia in any of the mice in vacci-
nated and non-vaccinated groups. Up to 33.3% (2 of 6) of mice
injected with vector only (IM) succumbed to challenge infection
during the 60 days of monitoring period. No mortality statistical
difference (P = 0.0870) was observed among groups (Fig. 5).cía et al., TcVac1 vaccine delivery by intradermal electroporation enhances
ce, Vaccine, https://doi.org/10.1016/j.vaccine.2018.11.041
Fig. 3. Histological visualization of acute phase lymphocyte infiltration in TcVac1
vaccinated/infected mice. Mice were given empty pCDNA3.1 vector or TcVac1 via
intramuscular (IM) injection or intradermal electroporation (IDE), challenged with
T. cruzi, and harvested at 60 days post-infection. Shown are representative images
of the heart and skeletal muscle sections stained with H&E (magnification 400).
Arrows show lymphocyte infiltration.
6 W. Hegazy-Hassan et al. / Vaccine xxx (xxxx) xxx3.4. Clinical and pathological (macroscopic and microscopic)
abnormalities in vaccinated and non-vaccinated mice post-challenge
infection
Immunization with TcVac1 produced no apparent presentation
of physical, or clinical macroscopic abnormalities. All mice injected
with pcDNA3.1 vector or TcVac1 by IDE or IM route exhibited no
inflammatory, degenerative, necrotic or proliferative injuries, thus,
suggesting that vaccine alone is non-toxic and safe to deliver. In
response to challenge infection with T. cruzi, 60–70% of mice that
were injected with empty vector only by IM or IDE route displayed
low levels of physical activity and nest building behavior,
decreased interaction with cage mates, hirsute bristling hair, and
poor general appearance. In comparison, mice vaccinated with
TcVac1 (IDE or IM route) had a healthy appearance with no observ-
able abnormalities in socialization, physical activity, or food and
water uptake. Macroscopic evaluation of the heart showed that
control mice injected with vector only (IDE or IM route) developed
bi-ventricular dilation (7 out of 10 mice) and epicardial hemor-
rhage (1 out of 10 mice) post challenge infection (Fig. 4). In com-
parison, mice immunized with TcVac1 (IDE or IM route)
exhibited no morphological changes of the heart post-challenge
infection.
Histological analysis of tissue sections was performed at sixty
days post-challenge infection when mice exhibited the end of the
acute infection phase. The histological evaluation of heart tissue
from representative mice in each group is shown in Fig. 3. We
noted mild, diffused inflammatory infiltrate, primarily constituted
by mononuclear lymphocytes, in the atria and ventricles of mice
that were injected with empty vector via IDE or IM route after chal-
lenge infection. In comparison, vaccinated/infected mice (TcVa-
c1_IDE/Tc and TcVac1_IM/Tc) exhibited a potent increase in
inflammatory infiltrate constituted of lymphocytes and polymor-
phonuclear leucocytes in the myocardium. The myocardial infiltra-
tion of inflammatory infiltrate was maximally noted in
TcVac1_IDE/Tc mice. Likewise, cardiomyocytes necrosis was
observed more frequently in TcVac1_IDE/Tc and TcVac1_IM/Tc
mice, while mice from the control groups presented infrequent
and moderate number of necrotic cells. The increase in myocardial
inflammatory infiltrate was associated with a decline in tissue par-
asite burden in vaccinated mice. We observed the largest number
of amastigotes nests in the atria and ventricles of mice in control
groups. The amastigotes nests’ counts were also significantly
higher in the left and right ventricle walls of acutely infected mice
in control groups than was observed in vaccinated mice. Overall,
we observed 5–8 foci of pseudocysts/microscopic field (mf) in
the cardiac tissue of mice in control groups and 0–2 foci of pseudo-
cysts/mf in the heart tissue of vaccinated mice. Minimal tissue par-
asite burden was observed in TcVac1_IDE/Tc group.
Similar to the heart tissue, skeletal muscle of mice in control
groups exhibited mild inflammation characterized by mononuclear
inflammatory infiltrate (macrophages and lymphocytes) and mod-
erate level of myocytes’ necrosis. In comparison, vaccinated mice
(TcVac1_IDE/Tc and TcVac1_IM/Tc) showed stark increase in skele-
tal muscle infiltration of inflammatory cells (polymorphnuclear
leukocytes, lymphocytes, and macrophages) and moderate level
of muscle fibers’ necrosis post challenge infection. Generally, skele-
tal muscle amastigotes nests were larger when compared to those
detected in the myocardial tissue. The abundance of amastigotes
nests in skeletal tissue of control groups was observed as follows:
pcDNA3.1_IDE/Tc (4 foci of pseudocysts/mf); pcDNA3.1_IM/Tc (3
foci of pseudocysts/mf). In comparison, vaccinated mice showed
a significantly lower number of parasitic pseudocysts (p < 0.01),
and fewer amastigotes nests were observed in skeletal tissue of
TcVac1_IDE/Tc mice (0–1 foci of pseudocysts/mf) than in the TcVa-
c1_IM/Tc mice (2 foci of pseudocysts/mf). Further, parasitic nestsPlease cite this article as: W. Hegazy-Hassan, J. A. Zepeda-Escobar, L. Ochoa-Gar
vaccine induced immune protection against Trypanosoma cruzi infection in miwere frequently presented adjacent to the inflammatory infiltrate
in the myocardial and skeletal tissue of the vaccinated/infected
mice (Fig. 3 and Table 2). Together, these results suggest that the
TcVac1 induced innate and adaptive immune cells responded to
challenge infection with vigorous proliferation and tissue migra-
tion, and provided a significant control of tissue parasite burden.
A higher degree of destruction of infected myocardial and skeletal
myocyte cells was also noted in vaccinated, vs. non-vaccinated,
mice post challenge infection.4. Discussion
In this study, we compared intradermal electroporation
approach and the conventional intramuscular administration tech-
nique to determine the differential efficiency of these two proto-
cols for the administration of TcVac1 vaccine in a murine model.
Candidate vaccines against Chagas disease have mainly been tested
by intramuscular immunization route. Several investigators have
reported that permeabilizing the target cells through electropora-
tion (EP) led to enhanced uptake of naked recombinant plasmid
and a superior expression of the gene of interest, and thereby an
improved immunization efficacy [12–14,16,17,20,27–29]. Othercía et al., TcVac1 vaccine delivery by intradermal electroporation enhances
ce, Vaccine, https://doi.org/10.1016/j.vaccine.2018.11.041
Fig. 4. Macroscopic evaluation of the heart for control mice (non-vaccinated) groups. Mice were vaccinated via IDE (n = 6) or IM (n = 4) with pcDNA3.1 empty plasmid and
evaluated after challenge infection, and postmortem macroscopic examination was established for the identification of heart abnormalities (epicardial hemorrhage and bi-
ventricular dilation). Data were recorded as case incidence of the heart abnormality for each mouse and recorded in a contingency table. Data were analyzed for statistical
differences using Chi-square test. (A) Shows the incidence of mice with epicardial hemorrhage for each control mice groups (P = 0.389). (B) shows the incidence of mice with
bi-ventricular dilation for each control mice groups (P = 0.091). pcDNA3.1_IDE/Tc: Control mice group vaccinated with empty plasmid via intradermal electroporation.
pcDNA3.1_IM/Tc: Control mice group vaccinated with empty plasmid via intramuscular injection.
Fig. 5. Survival percentage of mice groups after T. cruzi infection. Mice were
monitored for 60 days for any sign of disease and survival. Survival data were
analyzed statistically through Mantel-Cox test, survival curves did not show any
significant differences (P = 0.0870).
W. Hegazy-Hassan et al. / Vaccine xxx (xxxx) xxx 7authors have shown that electroporation, after intradermal or
intramuscular injection of DNA vaccines provide an efficient sys-
tem to activate antigen presenting cells (APCs), mainly dendritic
cells, since they are directly transfected at the site of DNA admin-
istration. The expressed antigen is presented in association of the
major histocompatibility complex (MHC) class 1 molecules [20].
This can subsequently stimulate the synthesis of antigen-specific
cytotoxic T lymphocytes in conjunction with T-helper cells. Skin
tissues, especially epidermis and dermis, are crowded with various
types of APCs including dendritic cells, in contrast with the muscle
tissue. Moreover, intradermal vaccine route specifically targetsTable 2















Mice were injected with empty pCDNA3.1 plasmid, or TcVac1 via intradermal electropora
in Materials and Methods. Tissue sections were examined for inflammatory infiltrate, nec
quantitative scoring of histopathological lesions is presented and explained in materia
microscopic fields/treatment/tissue and were analyzed for statistical differences using as
groups (TcVac1-IDE or -IM) vs control groups (pcDNA3.1-IDE or IM) respectively.
Please cite this article as: W. Hegazy-Hassan, J. A. Zepeda-Escobar, L. Ochoa-Gar
vaccine induced immune protection against Trypanosoma cruzi infection in midermal DCs and macrophages that, when activated, will carry vac-
cine components to draining lymph by passive diffusion or cell
transport of antigens. Afterwards, presentation of the antigens to
immature CD4+ and CD8+ T cells, leads to their activation, as well
as, the activation of specific B cells within the germinative center.
Finally, the generation of a pool of specific memory T and B cells in
the secondary lymphoid organs (draining lymph nodes and bone
marrow) and in the periphery (skin and mucosa) is also noted by
IDE delivery of candidate antigens [30]. Other studies compared
the effect of plasmid vaccination via intradermal (ID) only vs intra-
dermal followed by electroporation (EP), they proved that EP + ID
showed better and higher antibody responses than ID only [31].
Therefore, we hypothesized that intradermal electroporation
would enhance the effectiveness of the DNA based vaccine against
Chagas disease.
It is important to note that both types of immune responses,
humoral and cellular, are necessary to control the infection. This
is evidenced by the findings that mice deficient in CD8+ T cell
and/or B cell function were susceptible to T. cruzi infection and
exhibited high parasitemia and mortality [32]. Thus, a candidate
vaccine capable of eliciting both B and T cell responses and Th1
cytokines is considered to offer the best protection from T. cruzi
infection. Our group has identified two vaccine candidates, named
TcG2 and TcG4, that when co-delivered as DNA-prime/DNA-boost
vaccine (TcVac1), elicited protective immunity and resistance
against T. cruzi infection in mice and dogs [5,10,11]. Along the













tion (IDE) or intramuscular (IM) route and challenged with T. cruzi (Tc) as described
rosis, and parasite nests as described by Barbabosa-Pliego and Slauson [24,45]. Semi-
l and methods section. Data represents the average score of the evaluation of 100
mean score of mice per group (n = 6). *: indicates statistical differences of vaccinated
cía et al., TcVac1 vaccine delivery by intradermal electroporation enhances
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8 W. Hegazy-Hassan et al. / Vaccine xxx (xxxx) xxxenhances the antigen-presenting capability of dendritic cells and
facilitates B- and T-cell-mediated immunity and plasmid DNA IL-
12 is a key cytokine involved in CD8+-T-cell activation and prolifer-
ation reported to enhance antiparasitic effects of vaccines [33].
However, when these adjuvant plasmids were tested without par-
asite specific antigens to prevent T. cruzi infection in mice they did
not show any specific-antibody responses [10,34,35]. Therefore,
the anti-T cruzi specific immune response observed in the present
report can be assumed to rely on the TcG2 and TcG4 parasite anti-
gens used in the candidate vaccine. The immune activation pro-
vided by the GM-CSF and IL-12 plasmids were not analyzed in
the present report.
In order to determine if vaccination via IDE or IM route elicited
similar (or different) levels of cellular immune responses, we eval-
uated the lymphocyte proliferation reaction post immunization
and challenge infection. While both IDE and IM modes of vaccine
delivery elicited antigen-specific lymphocytes’ proliferation
(TcG4 > TcG2), the extent of antigen-specific lymphocytes’ prolifer-
ation was higher in the TcVac1_IDE than in TcVac1_IM group
(p < 0.0001). Importantly, the vaccine induced T cells exhibited a
better expansion and rapid effector function in controlling the tis-
sue parasite burden in mice immunized via the IDE route. A better
protection from challenge infection was associated with increased
frequency of TcG2- and TcG4-specific lymphocytes’ proliferation in
TcVac1_IDE vs. TcVac1_IM group. Our data allow us to surmise that
IDE delivery of tcVac1 enhances the generation of antigen-specific
memory T cells that are capable of responding to pathogen expo-
sure, and thus provided a better vaccine efficiency.
Our finding of higher levels of humoral response post-
immunization and post-challenge infection also favored IDE over
IM vaccination system (Fig. 1). The TcVac1_IDE mice exhibited
higher levels of the TcG2- and TcG4-specific IgG2a/b response
post-vaccination a significant increase in antigen- and parasite-
specific IgG2a/b and IgG1 levels post-challenge infection. Both
IgG1 and IgG2 antibody subtypes are proposed to be involved in
the elimination of blood forms of parasites and in a reduction of
animal mortality rate during the acute phase of infection [36].
The IgG2a/b generally constitute prevalent immune response
against carbohydrate/polysaccharide antigens, and IgG1s are pre-
dominantly considered to recognize proteins and polypeptide anti-
gens bound to the Fc receptor of phagocytic cells and participate in
activation of the complement cascade via binding to C1 complex.
Whether the TcG2 and TcG4 antigens are post-transnationally
modified, or whether the IDE delivery of TcVac1 enhances the
post-translational modification of TcG2 and TcG4 leading to
increase in IgG2a/b response is not known. However, our data sug-
gest that IDE route of TcVac1 delivery is more effective in eliciting a
predominant IgG2a/b response over IgG1 for both pre- and post-
infection phases, suggesting a skewed Th1 immune profile in
experimental mice.
Studies conducted in canine, bovine, primates and humans,
indicated that IM vaccination with naked DNA yields low expres-
sion level of the recombinant antigen, which in turn induces a sub-
optimal immune response. This is explained by the fact that
muscle tissue is not an efficient site for antigen presentation,
because of a lack of appropriate quantities of DCs, macrophages
and lymphocytes. Therefore, larger amounts of DNA vaccine dose
delivery by IM route was required to establish a strong immune
response in mice and larger species (e.g. dogs, pigs, humans). Com-
paratively, IDE delivery of the DNA vaccine requires smaller
amounts of the plasmid DNA to achieve strong immune responses,
and thus offers significant savings in time, cost and effort for vac-
cine production and delivery [11,37–39]. Thus, IDE delivery of
naked plasmids could favorably compete with other vaccine
protocols that include efficient antigen expression vectors, such
as Adenovirus or Salmonella [40,41].Please cite this article as: W. Hegazy-Hassan, J. A. Zepeda-Escobar, L. Ochoa-Gar
vaccine induced immune protection against Trypanosoma cruzi infection in miBlood parasitemia was not detected during the acute experi-
mental phase in any mice from any group, which indicates that
the strain Sylvio X10/4 of T. cruzi has a strong tissue tropism. This
strain behavior was previously reported by Marinho et al., 2004,
who described the absence of a patent acute phase as well as par-
asitemia in the weeks following the infection, when using Silvio
X10/4 T. cruzi parasite stain, with various mouse strains [42]. Addi-
tionally, they reported the presence of parasite nests, which were
totally ignored by the immune system in mice myocardial tissue.
In the present study also, we observed mild, diffused tissue infiltra-
tion of inflammatory infiltrate that was not localized close to par-
asites nests in non-vaccinated/infected animals. In contrast, tissue
inflammatory infiltrate was strongly associated with the parasite
nests, and contributed to control of size and number of tissue par-
asite nests in the vaccinated (TcVac1_IM/Tc and TcVac1_IDE/Tc)
mice. Thus, vaccinated/challenged mice exhibited an ability to con-
trol the parasite-mediated tissue destruction that was apparent by
the macroscopic and microscopic observation of apparently
healthier tissue.
The major pathological manifestations for chagasic cardiomy-
opathy in mice are cardiomegaly with hypertrophy of cardiac tis-
sue, dilation of the heart chambers and aneurism mostly in the
left ventricle associated with strong inflammation, necrotic car-
diomyocytes and fibrosis [7]. The IDE vaccination protocol altered
the histopathological developments in the myocardium of acutely
infected mice through induction of focal, parasite-specific inflam-
mation; moreover, vaccinated mice produced more antibodies
and displayed a stronger cellular immune response, which were
capable of reducing the number of amastigotes nests in mice heart
tissue (Table 2). However, our observations of cardiomyocytes
necrosis in TcVac1_IDE/Tc mice (Fig. 3) suggest that inflammatory
responses, if persistent, can also be injurious to the host. This inter-
pretation is consistent with studies in IL-4 deficient mice, which
were able to develop a strong Th1 type immune response and con-
trol acute parasitic burden but also developed exacerbated inflam-
mation in the myocardial tissue [43]. Future studies will be
required to determine if TcVac1_IDE induced inflammatory
responses subside with control of parasite and do not constitute
a risk factor in causing consistent, long-term tissue damage in
the host. Indeed, mice vaccinated with TcG2 and TcG4 antigens
by DNA-prime/protein boost approach exhibited a predominance
of type 1 inflammatory response capable of controlling circulating
and tissue parasites in acute phase, and then switched to
immunomodulatory, tissue-healing type 2 response thus providing
protection to the heart [44]. Thus, we believe that IDE would offer
an enhanced protective efficacy of TcVac1 against acute infection
and chronic Chagas disease.5. Conclusion
Both protocols of TcVac1 vaccination (IDE and IM), protected
against an acute T. cruzi infection, enhanced survival rate, milder
macroscopic heart pathologies and decreased tissue (heart and
skeletal muscle) parasite burden than was noted in non-
vaccinated/infected mice. The IDE delivery offered a more efficient
vaccination system than the IM route. This was evidenced by
induction of higher levels of antigen-specific, Th1 type cellular
and humoral immune responses that expanded in response to
challenge infection and provided a stronger infiltration of inflam-
matory cells capable of controlling the parasite nests in the heart
and skeletal tissues in mice vaccinated with TcVac1 by IDE route
than that observed in mice vaccinated via IM route. We conclude
that IDE delivery enhances protective efficacy of TcVac1 vaccine
in mice.cía et al., TcVac1 vaccine delivery by intradermal electroporation enhances
ce, Vaccine, https://doi.org/10.1016/j.vaccine.2018.11.041
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